What does this research mean for the field?

In patients with uterine cancer, administering the majority of early immune checkpoint inhibitor infusions before 1 PM is associated with lower rates of steroid-requiring immune-related adverse events, though this effect is sensitive to the specific time cutoff used and does not impact survival. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This analysis investigates the impact of administration timing of immune checkpoint inhibitors on toxicity and survival among uterine cancer patients.

May 30, 2026Journal of Clinical Oncology

Association of immune checkpoint inhibitor administration timing with toxicity and survival in uterine cancer: A real-world analysis.

View Full Paper

Ask AI

Bookmark

Authors

MMMeghan McGonagle SJSara Jubas KCKevin Chen

Discussion

Member takes

Overview

Retrospective cohort study reveals timing of immune checkpoint inhibitors affects toxicity in uterine cancer, suggesting importance for treatment optimization.

Key Points

This analysis investigates the impact of administration timing of immune checkpoint inhibitors on toxicity and survival among uterine cancer patients.
Conducted a retrospective cohort study of 290 patients with uterine cancer receiving intravenous ICIs
Categorized patients based on early (greater than 50% of infusions before 1 PM) or late administration
Analyzed outcomes including steroid-requiring immune-related adverse events (SRirAEs), progression-free survival, and overall survival.
SRirAEs were significantly lower in the early group compared to the late group (16% vs 33%, p=0.001)
No significant difference in rwPFS (14.4 vs 15.6 months; HR 1.02, 95% CI 0.74-1.41) or rwOS (42 vs 35 months; HR 1.04, 95% CI 0.70-1.54) across groups
Further subgroup analysis showed similar SRirAE rates among those who received infusions all before or after 1 PM (18% vs 21%, p=0.71) with no significant rwPFS or rwOS differences.

Cite This Study

McGonagle et al. (2026) studied this question.

synapsesocial.com/papers/6a1a82d50307b785094347ff https://doi.org/10.1200/jco.2026.44.16_suppl.e17640

View Full Paper

Ask AI

Bookmark

May 30, 2026Journal of Clinical Oncology

Association of immune checkpoint inhibitor administration timing with toxicity and survival in uterine cancer: A real-world analysis.

View Full Paper

Ask AI

Bookmark

Authors

MMMeghan McGonagle SJSara Jubas KCKevin Chen

Discussion

Member takes

Overview

Retrospective cohort study reveals timing of immune checkpoint inhibitors affects toxicity in uterine cancer, suggesting importance for treatment optimization.

Key Points

This analysis investigates the impact of administration timing of immune checkpoint inhibitors on toxicity and survival among uterine cancer patients.
Conducted a retrospective cohort study of 290 patients with uterine cancer receiving intravenous ICIs
Categorized patients based on early (greater than 50% of infusions before 1 PM) or late administration
Analyzed outcomes including steroid-requiring immune-related adverse events (SRirAEs), progression-free survival, and overall survival.
SRirAEs were significantly lower in the early group compared to the late group (16% vs 33%, p=0.001)
No significant difference in rwPFS (14.4 vs 15.6 months; HR 1.02, 95% CI 0.74-1.41) or rwOS (42 vs 35 months; HR 1.04, 95% CI 0.70-1.54) across groups
Further subgroup analysis showed similar SRirAE rates among those who received infusions all before or after 1 PM (18% vs 21%, p=0.71) with no significant rwPFS or rwOS differences.

Cite This Study

McGonagle et al. (2026) studied this question.

synapsesocial.com/papers/6a1a82d50307b785094347ff https://doi.org/10.1200/jco.2026.44.16_suppl.e17640

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark